Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Zhou, J; Sun, YK; Zhang, W; Yuan, JJ; Peng, Z; Wang, W; Gong, JF; Yang, L; Cao, YS; Zhao, H; Chen, C; Wang, WF; Shen, L; Zhou, AP

Shen, L (通讯作者)，Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Fu Cheng Rd 52, Beijing 100142, Peoples R China.;Zhou, AP (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Natl Clin Res Ctr Canc,Canc Hosp, 17 Panjiayuannanli St, Beijing 100021, Peoples R China.

HEPATOLOGY, 2023; 77 (1): 65

Abstract

Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death-li......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索